Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indeglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 5/20 | 1.00 |
| ▸ | PPARD known ✓ | Q03181 | 5/20 | 1.00 |
| ▸ | PPARA known ✓ | Q07869 | 5/20 | 1.00 |
| ▸ | HTR6 | P50406 | 15/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR1F | P30939 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indeglitazar SCHEMBL3019199 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL4605850 | 0.97 | PPARG (0.94) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL4605145 | 0.97 | PPARG (0.94) | PPARGPPARDPPARAHTR6HTR1A | |
| Indeglitazar SCHEMBL30153666 | 0.95 | PPARG (0.90) | PPARGPPARDPPARAHTR6HTR1A | |
| Indeglitazar SCHEMBL30153667 | 0.95 | PPARG (0.90) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL14605552 | 0.95 | PPARG (0.90) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL352303 | 0.95 | PPARG (0.90) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL3034510 | 0.94 | PPARG (0.89) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL14606001 | 0.94 | PPARG (0.88) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL5659494 | 0.94 | PPARG (0.88) | PPARGPPARDPPARAHTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743083-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | Pleiogenix Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| US-20260060958-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | PLEIOGENIX INC (US) | 2026-03-05 | — | — | US | claimed |
| US-12485106-B2 | Methods of treating fibrotic liver diseases or conditions with indeglitazar | PLEIOGENIX INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-20250319064-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | PLEIOGENIX INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-12257234-B2 | Methods of treating fibrotic liver diseases or conditions with indeglitazar | PLEIOGENIX INC. (US) | 2025-03-25 | — | — | US | claimed |
| WO-2025019330-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | PLEIOGENIX INC. (US) | 2025-01-23 | — | — | WO | claimed |
| US-20250017901-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | PLEIOGENIX INC (US) | 2025-01-16 | — | — | US | claimed |
| WO-2024251233-A1 | USE OF PPAR FULL AGONIST IN COMBINATION WITH THR-β AGONIST IN RESISTING OF METABOLIC-RELATED DISEASES | 成都微芯药业有限公司 | 2024-12-12 | — | — | WO | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| EP-4304719-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2024-01-17 | — | — | EP | claimed |
| CN-117122695-A | Hyaluronic acid functionalized conjugate for targeted activation of CD44 molecules, and preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-11-28 | — | — | CN | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023072010-A1 | USE OF PPAR AGONIST IN PREPARATION OF DRUG FOR TREATING ACUTE MYELOID LEUKEMIA | 厦门大学附属第一医院 | 2023-05-04 | — | — | WO | claimed |
| CN-115068618-A | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof | 厦门大学附属第一医院 | 2022-09-20 | — | — | CN | claimed |
| WO-2022189531-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2022-09-15 | — | — | WO | claimed |
| EP-4056231-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2022-09-14 | — | — | EP | claimed |
| CN-114949230-A | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof | 厦门大学附属第一医院 | 2022-08-30 | — | — | CN | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060958-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | MMP3, FIBP, FGF23 | PPARG 4001/4885PPARD 1940/4885PPARA 2680/4885 |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | PPARG 140/4885PPARD 559/4885PPARA 174/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885PPARD 614/4885PPARA 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.